Saxenda Explained: How It Works and Who It's For

Saxenda at a glance:

• Drug class: GLP-1 receptor agonist
• Manufacturer: Novo Nordisk
• FDA approved: 2014
• Route: subcutaneous injection (multi-dose pen)
• Typical frequency: once daily
• Half-life: approximately 13 hours
• Cash price (US): $1,200-$1,400/month without insurance
• Receptor target: GLP-1 receptor

If you're trying to figure out whether Saxenda is right for you — or for someone you care about — the right starting point is the basic biology. Saxenda is a glp-1 receptor agonist made by Novo Nordisk and approved by the FDA in 2014. Mean weight loss of 8% of body weight at 56 weeks in SCALE trials — modest compared with semaglutide or tirzepatide.

What is Saxenda?

Saxenda is liraglutide dosed for weight management. The same GLP-1 receptor agonist used for diabetes (Victoza) but titrated to a higher 3.0 mg/day target dose.

Saxenda is manufactured by Novo Nordisk and is a brand name for the generic compound liraglutide. Saxenda was approved by the FDA in 2014. Its approved indications include chronic weight management in adults with BMI ≥30, or ≥27 with comorbidities, weight management in adolescents 12+ with obesity. Off-label use happens in clinical practice but is the prescriber's responsibility.

The drug class glp-1 receptor agonist works by acting at the GLP-1 receptor. We cover the details below.

How Saxenda Works in the Body

Saxenda is liraglutide dosed for weight management. The same GLP-1 receptor agonist used for diabetes (Victoza) but titrated to a higher 3.0 mg/day target dose. The receptor target — GLP-1 receptor — drives the downstream effects users care about: mean weight loss of 8% of body weight at 56 weeks in scale trials — modest compared with semaglutide or tirzepatide.

The pharmacokinetics matter for daily use. Saxenda has a half-life of approximately 13 hours, which determines how often it is dosed. The standard route of administration is subcutaneous injection (multi-dose pen), and the typical schedule is once daily.

For more detail on the underlying biology, see our breakdown of how Saxenda works.

Who Uses Saxenda?

Saxenda is most relevant for people whose situation maps to its approved indications: chronic weight management in adults with BMI ≥30, or ≥27 with comorbidities; weight management in adolescents 12+ with obesity.

People who should avoid Saxenda include those with the following:

• personal or family history of medullary thyroid carcinoma
• MEN 2 syndrome
• pregnancy

Common and Serious Side Effects

The most commonly reported side effects of Saxenda include:

• nausea
• diarrhea
• constipation
• vomiting
• headache
• injection-site reactions

Serious risks — uncommon but worth knowing — include:

• pancreatitis
• gallbladder disease
• thyroid C-cell tumors (boxed warning)
• acute kidney injury

We have a more detailed breakdown in our Saxenda side-effects guide.

Saxenda vs Alternatives

Most patients now choose Wegovy or Zepbound over Saxenda for greater weight loss with weekly (rather than daily) dosing. If you are weighing Saxenda against another option, our comparison pages include Saxenda Side Effects Decoded: What's Normal vs. What Isn't, Does Saxenda Really Work? An Evidence-Based Results Review, Saxenda Price Decoded: Insurance, Coupons, and Cash-Pay Options.

Bottom Line

Saxenda delivers what its label says it delivers. The case for it (or against it) comes down to your specific situation, not abstract comparisons. Multiple randomized controlled trials support its efficacy. If you are considering Saxenda, talk to a licensed clinician first — particularly if you take other medications.

Frequently Asked Questions

Related Reading

• Saxenda Side Effects Decoded: What's Normal vs. What Isn't
• Does Saxenda Really Work? An Evidence-Based Results Review
• Saxenda Price Decoded: Insurance, Coupons, and Cash-Pay Options
• Saxenda for Weight Management: How Much Can You Lose?
• What Is Ozempic? Everything You Should Know Before Starting
• Is Ozempic Safe? An Honest Look at the Side-Effect Profile

Sources

• Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989.
• Marso SP et al. Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes (SUSTAIN-6). NEJM 2016;375:1834.
• Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE). NEJM 2015;373:11.

This page is informational only and is not medical advice. Consult a licensed clinician before starting, stopping, or changing any medication.